COMPANY

Werewolf Therapeutics

Keywords: oncology immunology cancer protein engineering Non-Hodgkin Lymphoma WTX-330 WTX-124

Location: Waltham, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

May 7, 2025 Trial start 1: A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma source ↗
Dec 6, 2022 Trial start Phase 1: WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma source ↗
Aug 15, 2022 Trial start Phase 1: Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors source ↗

2028-08 (ESTIMATED) · 1 · A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma · NCT06939283

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT05479812	Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors	Phase 1	Completed	Aug 15, 2022	Apr 22, 2026 (actual)
NCT06939283	A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma	1	Active, not recruiting	May 7, 2025	2028-08 (estimated)
NCT05678998	WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma	Phase 1	Completed	Dec 6, 2022	Dec 23, 2024 (actual)